InsiderTrades.com logo

Ken Takanashi Biography and Net Worth

Director of WAVE Life Sciences
  • LinkedIn
  • Phone
  • Email
  • Website


Ken Takanashi has served on Wave’s board of directors for more than ten years and currently serves as Senior Executive Vice President, Representative Director at Shin Nippon Biomedical Laboratories, Ltd. (SNBL), a contract research organization that provides preclinical and clinical services for drug development to pharmaceutical and biotech companies and conducts translational research business. Mr. Takanashi has served in various executive management and director roles at SNBL and its affiliates since 2004. Since 2016, Mr. Takanashi has also served on the board of directors of Satsuma Pharmaceuticals, Inc., a biopharmaceutical company that was previously publicly traded and became a privately held company and wholly owned subsidiary of SNBL on June 8, 2023. Mr. Takanashi also serves as a member of the board of directors of TMS Co., Ltd., a biopharmaceutical company listed on the Tokyo Stock Exchange, since March 2022. Mr. Takanashi has experience working for more than 30 global companies, as well as establishing various biotech companies and contract research organizations. Mr. Takanashi earned an M.B.A. from the University of Warwick and received his bachelor’s degree from the University of Tokyo and is a Chartered Public Accountant.

What is Ken Takanashi's net worth?

The estimated net worth of Ken Takanashi is at least $43.56 million as of August 5th, 2025. Mr. Takanashi owns 5,716,303 shares of WAVE Life Sciences stock worth more than $43,558,229 as of December 5th. This net worth approximation does not reflect any other investments that Mr. Takanashi may own. Learn More about Ken Takanashi's net worth.

How do I contact Ken Takanashi?

The corporate mailing address for Mr. Takanashi and other WAVE Life Sciences executives is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. WAVE Life Sciences can also be reached via phone at (656) 236-3388 and via email at [email protected]. Learn More on Ken Takanashi's contact information.

Has Ken Takanashi been buying or selling shares of WAVE Life Sciences?

Ken Takanashi has not been actively trading shares of WAVE Life Sciences within the last three months. Most recently, Ken Takanashi sold 4,872 shares of the business's stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $8.75, for a transaction totalling $42,630.00. Following the completion of the sale, the director now directly owns 5,716,303 shares of the company's stock, valued at $50,017,651.25. Learn More on Ken Takanashi's trading history.

Who are WAVE Life Sciences' active insiders?

WAVE Life Sciences' insider roster includes Paul Bolno (CEO), Chris Francis (insider), Christian Henry (Director), Kyle Moran (CFO), Ken Takanashi (Director), and Gregory Verdine (Director). Learn More on WAVE Life Sciences' active insiders.

Are insiders buying or selling shares of WAVE Life Sciences?

In the last twelve months, insiders at the sold shares 8 times. They sold a total of 467,533 shares worth more than $4,461,142.90. The most recent insider tranaction occured on November, 13th when Director Adrian Rawcliffe sold 16,115 shares worth more than $109,420.85. Insiders at WAVE Life Sciences own 24.0% of the company. Learn More about insider trades at WAVE Life Sciences.

Information on this page was last updated on 11/13/2025.

Ken Takanashi Insider Trading History at WAVE Life Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/5/2025Sell4,872$8.75$42,630.005,716,303View SEC Filing Icon  
See Full Table

Ken Takanashi Buying and Selling Activity at WAVE Life Sciences

This chart shows Ken Takanashi's buying and selling at WAVE Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

WAVE Life Sciences Company Overview

WAVE Life Sciences logo
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Read More

Today's Range

Now: $7.62
Low: $7.12
High: $7.68

50 Day Range

MA: $7.49
Low: $6.67
High: $9.04

2 Week Range

Now: $7.62
Low: $5.28
High: $15.72

Volume

2,519,503 shs

Average Volume

2,285,890 shs

Market Capitalization

$1.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A